Skip to main
BNGO
BNGO logo

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics demonstrated a significant operational improvement in 2Q25, with the sale of 7,233 nanochannel array flowcells reflecting a 17% increase from the previous year. Adjusted revenue from consumables, software, and other services grew by 11% year-over-year, driven by a robust 16% increase in consumables and software revenues. Additionally, the company expects new OGM installations to rise to between 20 and 25 in FY2025, up from an anticipated range of 15 to 20, indicating positive momentum in its product offerings and market demand.

Bears say

Bionano Genomics Inc. faces significant risks that contribute to a negative outlook on its stock, including potential lower-than-expected market uptake of its products and reduced utilization of installed systems. The company's projections indicate a price objective of approximately $11, based on conservative revenue multiples and current financial metrics, which raises concerns about its capacity to achieve these targets amid operational challenges. Additionally, the need to secure further capital poses a threat to financial stability, coupled with the risk of shareholder dilution, all of which could hinder the company's growth and investor confidence.

Bionano Genomics (BNGO) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Buy based on their latest research and market trends.

According to 3 analysts, Bionano Genomics (BNGO) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.